Koers Protalix Biotherapeutics Inc TEL AVIV STOCK EXCHANGE
Aandelen
US74365A1016
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 52,7 mln. 19,69 mld. 48,75 mln. | Omzet 2025 * | 101 mln. 37,88 mld. 93,79 mln. | Marktkapitalisatie | 76,25 mln. 28,49 mld. 70,53 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 8 mln. 2,99 mld. 7,4 mln. | Nettowinst (verlies) 2025 * | 54 mln. 20,17 mld. 49,95 mln. | EV/omzet 2024 * | 1,45 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 0,75 x |
K/w-verhouding 2024 * |
8,67
x | K/w-verhouding 2025 * |
1,65
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 85,42% |
Recentste transcriptie over Protalix Biotherapeutics Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Dror Bashan
CEO | Chief Executive Officer | 57 | 30-06-19 |
Eyal Rubin
DFI | Director of Finance/CFO | 48 | 22-07-19 |
Yael Hayon
CTO | Chief Tech/Sci/R&D Officer | 41 | 05-07-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Pol Boudes
BRD | Director/Board Member | 67 | 01-12-19 |
Gwen Melincoff
BRD | Director/Board Member | 72 | 01-12-19 |
Aharon Schwartz
BRD | Director/Board Member | 80 | 01-11-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+16,59% | 44,44 mld. | |
+41,02% | 39,84 mld. | |
-10,62% | 37,68 mld. | |
+29,92% | 31,46 mld. | |
-9,23% | 27,02 mld. | |
+12,34% | 26,29 mld. | |
+41,53% | 13,8 mld. | |
+31,49% | 12,46 mld. | |
-7,40% | 11,26 mld. |